Your browser doesn't support javascript.
loading
Influence of Pathophysiological Patterns of Coronary Artery Disease on Immediate Percutaneous Coronary Intervention Outcomes.
Collet, Carlos; Munhoz, Daniel; Mizukami, Takuya; Sonck, Jeroen; Matsuo, Hitoshi; Shinke, Toshiro; Ando, Hirohiko; Ko, Brian; Biscaglia, Simone; Rivero, Fernando; Engstrøm, Thomas; Arslani, Ketina; Leone, Antonio Maria; van Nunen, Lokien X; Fearon, William F; Christiansen, Evald Høj; Fournier, Stephane; Desta, Liyew; Yong, Andy; Adjej, Julien; Escaned, Javier; Nakayama, Masafumi; Eftekhari, Ashkan; Zimmermann, Frederik M; Sakai, Koshiro; Storozhenko, Tatyana; da Costa, Bruno R; Campo, Gianluca; West, Nick E J; De Potter, Tom; Heggermont, Ward; Buytaert, Dimitri; Bartunek, Jozef; Berry, Colin; Collison, Damien; Johnson, Thomas; Amano, Tetsuya; Perera, Divaka; Jeremias, Allen; Ali, Ziad; Pijls, Nico H J; De Bruyne, Bernard; Johnson, Nils P.
Afiliação
  • Collet C; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Munhoz D; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Advanced Biomedical Sciences, University Federico II, Naples, Italy.
  • Mizukami T; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Division of Clinical Pharmacology, Department of Pharmacology, Showa University, Tokyo, Japan.
  • Sonck J; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Matsuo H; Department of Cardiovascular Medicine, Gifu Heart Center, Gifu, Japan.
  • Shinke T; Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
  • Ando H; Department of Cardiology, Aichi Medical University, Aichi, Japan.
  • Ko B; Monash Cardiovascular Research Centre, Monash University and Monash Heart, Monash Health, Clayton, Victoria, Australia.
  • Biscaglia S; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy.
  • Rivero F; Cardiac Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain.
  • Engstrøm T; Rigshospitalet, University of Copenhagen, Denmark.
  • Arslani K; Rigshospitalet, University of Copenhagen, Denmark.
  • Leone AM; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome Italy; IRCCS, Catholic University School of Medicine, Largo A. Gemelli, Rome, Italy; Center of Excellence in Cardiovascular Diagnostics and Therapeutic, Ospedale Fabenefratelli Isola Tiberina Gem
  • van Nunen LX; Department of Cardiology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Fearon WF; Division of Cardiovascular Medicine and Stanford Cardiovascular Institute, Stanford University School of Medicine and VA Palo Alto Health Care System, Palo Alto, CA.
  • Christiansen EH; Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark.
  • Fournier S; Department of Cardiology, University Hospital of Lausanne, Lausanne, Switzerland.
  • Desta L; Department of Cardiology, Karolinska University Hospital, Solna, Stockholm, Sweden.
  • Yong A; Concord Repatriation General Hospital, University of Sydney, New South Wales, Australia.
  • Adjej J; Department of Cardiology, Arnault Tzanck Institute Saint Laurent du Var, France.
  • Escaned J; Instituto de Investigacion Sanitaria del Hospital Clinico San Carlos and Complutense University, Madrid, Spain.
  • Nakayama M; Department of Cardiology, Tokyo D Tower Hospital, Tokyo, Japan.
  • Eftekhari A; Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
  • Zimmermann FM; Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
  • Sakai K; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Medicine, Division of Cardiology, Showa University School of Medicine, Tokyo, Japan.
  • Storozhenko T; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Prevention and Treatment of Emergency Conditions, L.T. Malaya Therapy National Institute NAMSU, Kharkiv, Ukraine.
  • da Costa BR; Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), Nuffield Department of Population Health, University of Oxford; Clinical Epidemiology & Health Care Research, Institute of Health Policy and Management Evaluation (IHPME), University of Toronto, Canada.
  • Campo G; Cardiology Unit, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy.
  • West NEJ; Abbott Vascular, Santa Clara, CA.
  • De Potter T; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Heggermont W; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Buytaert D; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Bartunek J; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
  • Berry C; School Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; NHS Golden Jubilee Hospital, Clydebank, United Kingdom.
  • Collison D; School Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, United Kingdom; NHS Golden Jubilee Hospital, Clydebank, United Kingdom.
  • Johnson T; University Hospitals Bristol & Weston NHS Foundation Trust, Bristol, United Kingdom.
  • Amano T; Department of Cardiology, Aichi Medical University, Aichi, Japan.
  • Perera D; School of Cardiovascular Medicine and Sciences, St Thomas' Hospital Campus, King's College London, London, United Kingdom.
  • Jeremias A; St Francis Hospital and Heart Center, Roslyn, NY.
  • Ali Z; St Francis Hospital and Heart Center, Roslyn, NY.
  • Pijls NHJ; Department of Cardiology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.
  • De Bruyne B; Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Cardiology, University Hospital of Lausanne, Lausanne, Switzerland.
  • Johnson NP; Weatherhead PET Center, Division of Cardiology, Department of Medicine, McGovern Medical School at UTHealth and Memorial Hermann Hospital, Houston, TX.
Circulation ; 2024 May 14.
Article em En | MEDLINE | ID: mdl-38742491
ABSTRACT

BACKGROUND:

Diffuse coronary artery disease (CAD) impacts the safety and efficacy of percutaneous coronary intervention (PCI). Pathophysiological CAD patterns can be quantified using fractional flow reserve (FFR) pullbacks incorporating the pullback pressure gradient (PPG) calculation. This study aimed to establish the capacity of PPG to predict optimal revascularisation and procedural outcomes.

METHODS:

This prospective, investigator-initiated, single-arm, multicentre study enrolled patients with at least one epicardial lesion with an FFR ≤ 0.80 scheduled for PCI. Manual FFR pullbacks were employed to calculate PPG. The primary outcome of optimal revascularisation was defined as a post-PCI FFR ≥ 0.88.

RESULTS:

993 patients with 1044 vessels were included. The mean FFR was 0.68 ± 0.12, PPG 0.62 ± 0.17, and post-PCI FFR 0.87 ± 0.07. PPG was significantly correlated with the change in FFR after PCI (r=0.65, 95% CI 0.61-0.69, p<0.001) and demonstrated excellent predicted capacity for optimal revascularisation (AUC 0.82, 95% CI 0.79-0.84, p<0.001). Conversely, FFR alone did not predict revascularisation outcomes (AUC 0.54, 95% CI 0.50-0.57). PPG influenced treatment decisions in 14% of patients, redirecting them from PCI to alternative treatment modalities. Periprocedural myocardial infarction occurred more frequently in patients with low PPG (<0.62) compared to those with focal disease (OR 1.71, 95% CI 1.00-2.97).

CONCLUSIONS:

Pathophysiological CAD patterns distinctly affect the safety and effectiveness of PCI. The PPG showed an excellent predictive capacity for optimal revascularisation and demonstrated added value compared to a FFR measurement.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Circulation Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Bélgica

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Circulation Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Bélgica